4DMedical Secures Commercial SimonMed Contract Across 170 US Imaging Centres
4DMedical secures commercial CT:VQ™ contract with SimonMed across 170 US imaging centres
4DMedical Limited (ASX: 4DX) has signed a commercial agreement with SimonMed Imaging for CT:VQ™ and LDAf™ deployment across SimonMed’s network of more than 170 outpatient imaging centres across 10 US states. The three-year agreement places 4DMedical’s quantitative cardiopulmonary analysis software into one of the largest outpatient imaging networks in the United States, supported by over 300 radiologists.
The partnership marks a significant commercial milestone for 4DMedical, with SimonMed moving directly to commercial deployment on a per-scan pricing basis under 4DMedical’s SaaS model. While not immediately financially material, the company describes this as a clear commercial win and material long-term opportunity, validating the transition from clinical validation at academic medical centres to scaled commercial deployment across high-volume outpatient networks.
SimonMed, headquartered in Scottsdale, Arizona, is recognised for its methodical approach to technology adoption, thoroughly validating new capabilities before deploying them at scale across its national network. The physician-led radiology group operates community-based imaging centres that serve millions of patients annually, representing a substantial addressable market for functional imaging software.
When big ASX news breaks, our subscribers know first
What is CT:VQ™ and why does outpatient deployment matter?
CT:VQ™ is software that extracts functional lung and cardiac information from standard CT scans without requiring additional contrast agents or nuclear medicine studies. The technology provides quantitative cardiopulmonary analysis that enables clinicians to detect conditions affecting millions of patients, including asthma and COPD, through objective assessment of regional lung function and cardiac risk markers.
The clinical value lies in transforming routine chest CT imaging into a diagnostic tool that delivers deeper insights for diagnosis, treatment planning, and patient management. Rather than requiring separate nuclear medicine ventilation-perfusion studies or contrast-enhanced cardiac imaging, CT:VQ™ derives functional data from conventional CT protocols already in use across imaging centres.
Outpatient imaging centres handle high volumes of routine scans, representing the volume opportunity for SaaS-based medical imaging software beyond hospital systems. SimonMed’s network processes millions of scans annually across diverse patient populations, providing significant scale potential for per-scan revenue models. The company’s reputation for rigorous technology validation before network-wide deployment serves as third-party endorsement of CT:VQ™’s clinical and operational readiness for scaled commercial use.
For investors, this deployment demonstrates market pull in the outpatient segment where volume economics drive SaaS revenue models. Academic medical centres provide clinical validation and publication evidence, whilst outpatient networks deliver the scan volume that translates into material revenue at scale.
Commercial structure and reimbursement pathway
The agreement delivers immediate clinical deployment on commercial terms from day one, with no evaluation or pilot phase preceding commercial rollout. Pricing is based on 4DMedical’s per-scan rates under its SaaS delivery model, with the company providing cloud-based software accessed across SimonMed’s network infrastructure.
The three-year agreement includes a strategic reimbursement collaboration beyond software deployment. SimonMed will support development of reimbursement evidence for CT:VQ™ and share insurance and claims data across its network to inform payor engagement strategies. This real-world data from a major outpatient provider strengthens 4DMedical’s evidence base for securing reimbursement coverage across public and private payors.
| Agreement Element | Detail |
|---|---|
| Contract type | Commercial (no evaluation phase) |
| Term | Three years |
| Pricing model | Per-scan SaaS rates |
| Products deployed | CT:VQ™ and LDAf™ |
| Reimbursement support | Claims data sharing for payor engagement |
Reimbursement coverage remains the key unlock for scaled US adoption of functional imaging technologies. Medicare and commercial insurance reimbursement determines whether ordering physicians can routinely integrate advanced imaging analysis into standard care pathways without requiring patients to bear out-of-pocket costs. SimonMed’s partnership provides 4DMedical with access to actual claims data across diverse payor contracts, insurance networks, and patient populations, informing the evidence package required to secure broader coverage determinations.
The immediate commercial deployment without an evaluation phase suggests SimonMed’s internal validation concluded that the technology delivers sufficient clinical and operational value to justify commercial pricing from first scan. For a network known for disciplined technology adoption, this decision signals confidence in both clinical utility and operational integration.
US market momentum following FDA clearance
CT:VQ™ has been deployed across leading Academic Medical Centres since receiving FDA clearance, establishing clinical validation foundations before extending into commercial outpatient networks. Management characterised the company’s US market trajectory as having “unstoppable momentum,” with the SimonMed partnership demonstrating progression from academic medical centres focused on clinical validation to large-scale imaging networks pursuing commercial deployment.
The strategic sequence reflects a deliberate commercialisation pathway. Academic medical centres provide clinical evidence, peer-reviewed publications, and physician education that establish credibility for new imaging technologies. Large outpatient networks deliver the scan volumes required to generate material revenue under per-scan pricing models. SimonMed’s decision to move directly to commercial deployment, bypassing extended evaluation periods, accelerates this transition.
Andreas Fouras, Managing Director, CEO and Founder, 4DMedical
“SimonMed is one of the largest and most influential outpatient imaging providers in the United States. Their decision to adopt CT:VQ™, moving directly to commercial deployment, is a major milestone for 4DMedical and a strong validation of both our technology and our clinical value.”
Fouras highlighted that the commercial structure of the agreement reflects growing confidence in CT:VQ™’s clinical and operational value. By enabling comprehensive cardiopulmonary analysis from a standard CT scan, including lung function assessment and cardiac risk insights, the software allows providers to extract greater value from existing imaging workflows without requiring additional patient procedures or specialised equipment.
The pattern of adoption demonstrates market pull rather than evaluation-phase uncertainty. Academic medical centres chose to implement CT:VQ™ for clinical research and complex case review; SimonMed chose to deploy it commercially for routine diagnostic workflows. This suggests the technology has crossed the threshold from experimental validation to operational readiness for high-volume deployment.
Clinical integration and care delivery
CT:VQ™ integrates with existing CT imaging workflows to provide deeper diagnostic insights without altering scanner protocols or requiring additional patient procedures. The software processes standard chest CT images to generate quantitative functional data on regional lung ventilation, perfusion, and cardiac risk markers. Radiologists receive these functional maps alongside conventional anatomical CT images, supporting more comprehensive interpretation and reporting.
Dr Sean Raj, Chief Medical Officer and Chief Innovation Officer at SimonMed, emphasised the potential for transforming routine imaging into quantitative, clinically actionable tools that support earlier disease identification and more precise risk stratification.
Dr Sean Raj, Chief Medical Officer and Chief Innovation Officer, SimonMed Imaging
“By extracting functional cardiopulmonary information directly from standard CT scans without additional contrast or nuclear medicine studies, we believe this technology has the potential to help physicians identify diseases that affect millions of patients, including asthma and COPD, earlier, stratify risk more precisely, and ultimately support more personalised care and better outcomes for patients.”
The clinical applications span pulmonary and cardiac assessment, with quantitative data supporting diagnosis and treatment planning across multiple disease states.
- Lung function assessment from standard CT scans provides regional ventilation analysis
- Cardiac risk insights without additional procedures deliver perfusion and vascular analysis
- Quantitative data supporting diagnosis and treatment planning replaces subjective visual interpretation
- No contrast agents or nuclear medicine studies required reduces patient risk and procedural complexity
Workflow integration into existing CT infrastructure supports adoption velocity by eliminating the need for separate imaging studies or specialised scanner modifications. Extracting more clinical value from scans already being performed aligns with healthcare efficiency priorities, particularly in outpatient settings where throughput and operational efficiency directly impact financial performance.
For clinicians, the technology addresses a diagnostic gap. Standard CT scans reveal anatomical structure but provide limited functional information about how well lungs are ventilating or how effectively blood is perfusing lung tissue. Nuclear medicine ventilation-perfusion scans provide functional data but require separate procedures, radioactive tracers, and specialised equipment. CT:VQ™ derives functional insights from the anatomical CT scan already being performed, combining structural and functional assessment in a single study.
The next major ASX story will hit our subscribers first
Strategic positioning in US functional imaging market
4DMedical has established deployment across leading academic medical centres and is now extending into scaled commercial outpatient networks, positioning the company across both clinical validation and revenue generation pathways. Management described 4DMedical as the “partner of choice” for next-generation CT-based functional imaging in the US market.
The dual-track deployment strategy leverages academic centres for credibility and evidence generation whilst pursuing high-volume outpatient networks for revenue scale. Academic medical centres publish clinical studies, present at medical conferences, and train radiologists and pulmonologists, building the evidence base that supports reimbursement applications and clinical adoption. Outpatient networks process millions of routine scans annually, providing the volume economics that drive SaaS revenue models.
Management highlighted increasing reimbursement visibility as a key factor expected to accelerate market adoption. Reimbursement coverage from Medicare and major commercial insurers removes the primary barrier to routine clinical use of advanced imaging technologies. SimonMed’s partnership directly supports this objective by providing real-world claims data across diverse payor contracts and patient populations.
The company expects momentum to accelerate further with growing evidence base and expanding commercial traction. Each academic medical centre deployment generates clinical publications and physician experience; each commercial network deployment generates claims data and real-world evidence. This flywheel effect strengthens both the clinical validation and economic case for broader adoption and reimbursement coverage.
For investors, the strategic positioning reflects progress across multiple value drivers. Academic centre deployment builds clinical credibility and publication evidence supporting regulatory approvals in additional markets and reimbursement applications. Commercial network deployment demonstrates operational readiness for scale and begins generating recurring per-scan revenue. The reimbursement pathway progresses through accumulation of claims data and clinical evidence, with each deployment contributing to the evidence package required for coverage determinations.
The market opportunity extends beyond the SimonMed network. Outpatient imaging in the US represents thousands of independent and network-affiliated centres processing tens of millions of chest CT scans annually. Functional imaging capabilities that integrate into existing workflows without requiring capital equipment purchases or workflow disruption address a substantial addressable market if reimbursement coverage is secured.
Want to Track 4DMedical’s US Commercial Expansion?
This SimonMed agreement marks 4DMedical’s transition from academic validation to scaled commercial deployment, positioning the company to generate recurring per-scan revenue across one of America’s largest outpatient imaging networks. With reimbursement pathways advancing and momentum building across both academic and commercial channels, the trajectory warrants close investor attention.
Stay informed on 4DMedical’s market progress and commercial milestones by visiting the 4DMedical investor centre. Access full ASX announcements, financial updates, and strategic developments as the company executes its US commercialisation strategy.